• 1
    The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypernsive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Journal of the American Medical Association 2002; 288:29812997.
  • 2
    National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. The New England Journal of Medicine 2003; 348:20592073.
  • 3
    National Emphysema Treatment Trial Research Group. Patients at high risk of death after lung-volume-reduction surgery. The New England Journal of Medicine 2001; 345:10751083.
  • 4
    Hulley SB, Cummings SR, Grady DG, Newman TB. Designing Clinical Research. Lippincott Williams and Wilkins: Philadelphia, 2007.
  • 5
    Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. Journal of the American Medical Association 2002; 288:24322440.
  • 6
    Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. The New England Journal of Medicine 1997; 336:11171124.
  • 7
    van der Ploeg AT, et al. A randomized study of algucosidase alfa in late-onset Pompe's disease. New England Journal of Medicine 2010; 362:13961406.
  • 8
    Müller HH, Schäfer H. A general statistical principle for changing a design any time during the course of a trial. Statistics in Medicine 2004; 23:24972508.
  • 9
    Gould AL, Shih WJ. Sample size re-estimation without unblinding for normally distributed outcomes with unknown variance. Communications in Statistics (A) 1992; 21:28332853.
  • 10
    Gould AL. Planning and revising the sample size in a trial. Statistics in Medicine 1995; 14:10391051.
  • 11
    Kieser M, Friede T. Simple procedures for blinded sample size adjustment that do not affect the type I error rate. Statistics in Medicine 2003; 22:35713581.
  • 12
    Xing B, Ganju J. A method to estimate the variance of an endpoint from an on-going blinded trial. Statistics in Medicine 2005; 24:18071814.
  • 13
    Läuter J. Exact t and F tests for analysing studies with multiple endpoints. Biometrics 1996; 52:964970.
  • 14
    Kropf S, Läuter J. Multiple tests for different sets of variables using a data-driven ordering of hypotheses, with an application to gene expression data. Biometrical Journal 2002; 44:789800.
  • 15
    Westfall PH, Kropf S, Finos L. Weighted FWE-controlling methods in high-dimensional situations. In Recent developments in multiple comparison procedures, Benjamini Y, Bretz F, Sarkar S (eds). Institute of Mathematical Statistics: Beachwood, Ohio, USA, 2004; 143154.
  • 16
    Hommel G, Kropf S. Tests for differentiation in gene expression using a data-driven order or weights for hypotheses. Biometrical Journal 2005; 47:554562.
  • 17
    Hogg RV, Fisher DM, Randles RH. A two-sample adaptive distribution-free test. Journal of the American Statistical Association 1975; 70:656661.
  • 18
    Edwards D. On model prespecification in confirmatory randomized studies. Statistics in Medicine 1999; 18:771785.
  • 19
    Brannath W, Gutjahr G, Bauer P. Probabilistic foundation of confirmatory adaptive designs. Journal of the American Statistical Association 2011. in press.